Device Trial Radar · NCT06005311
Microfluidic Chip Method Versus Density-gradient Centrifugation Method in IVF
Last checked: Nov 19, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,136
Planned (sponsor's estimate)
Start
Nov 1, 2024
Primary completion
Nov 30, 2027
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Professor Ernest Hung-Yu NgAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 43 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Infertile patients attending IVF treatment at the Centre of Assisted Reproduction and Embryology, Queen Mary Hospital and Kwong Wah Hospital will be recruited during ovarian stimulation for IVF. Subsequently, they will be randomly assigned on the day of oocyte retrieval by a laboratory staff into one of the following two groups: (1) the microfluidic chip group and (2) the density gradient group for sperm preparation and subsequent use in fertilization. Other IVF procedures will be the same as our usual practice. Both patients and clinicians were blinded from the group allocation i.e. a double blind study. The primary outcome is the cumulative live birth rate defined as the number of pregnancies leading to live birth within 6 months of randomisation.
Conditions
- Infertility
Interventions
Microfluidic chipDevice
The Sperm Separation Device - ZyMōt Multi 850µL (ZyMōt Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 μL of the semen sample will be inserted into the inlet port of the device and 750 μL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 μL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.
Density-gradient centrifugationDevice
After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
Primary outcomes
What the sponsor says the trial is designed to measure.
- cumulative live birth rateTime frame: within 6 months of randomisation.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Obstetrics and Gynaecology
Hong Kong, Hong Kong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.